loading page

Developing practical recommendations for drug-disease interactions in patients with hypertension
  • +3
  • Kübra Özokcu,
  • Maaike Diesveld,
  • Suzan Gipmans,
  • Laura Peeters,
  • Bert-Jan van den Born,
  • Sander Borgsteede
Kübra Özokcu
Meander Medisch Centrum Locatie Amersfoort
Author Profile
Maaike Diesveld
Health Base Foundation
Author Profile
Suzan Gipmans
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie
Author Profile
Laura Peeters
Maasstad Hospital
Author Profile
Bert-Jan van den Born
Academic Medical Center
Author Profile
Sander Borgsteede
Health Base Foundation

Corresponding Author:[email protected]

Author Profile


Abstract Aims This study aims to assess the safety of medication that can affect blood pressure in patients with hypertension and provide practical recommendations for healthcare professionals. Methods For the development of recommendations for the drug-disease interaction (DDSI) hypertension, a six-step plan that combined literature selection and multidisciplinary expert opinion was used. The process involved (1) defining the scope of the DDSI and selecting relevant drugs, (2) collecting evidence, (3) data-extraction, (4) reaching of expert consensus, (5) publication and implementation of the recommendations in healthcare systems and (6) updating of the information. Results An increase of 10 mmHg in systolic blood pressure and 5 mmHg in diastolic blood pressure was defined as clinically relevant. Corticosteroids, danazol, and yohimbine caused a clinically relevant DDSI with hypertension. Several other drugs with warnings for hypertension in the official product information, were assessed to have no clinically relevant DDSI due to minor influence or lack of data on blood pressure. Drugs with evidence for a relevant change in blood pressure which are prescribed under close monitoring of blood pressure according to clinical guidelines, were deemed to be not clinically relevant for signalling. Conclusions This study provides specific recommendations that can be implemented directly in clinical practice, potentially resulting in safer drug use in patients with hypertension and better healthcare by reducing alert fatigue. Future research should focus on evaluating the effectiveness of implementation strategies and their impact on reducing unsafe use of medication in patients with hypertension.